EUVIMEDEUVIMED entdecken
Crossref

New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice

Clémence M Canivet, Jérôme Boursier, Rohit Loomba

Seminars in Liver Disease · 2024-02 · 44 (01) · 035-042

DOI: 10.1055/s-0044-1785196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Liver Disease, online erschienen am 26.03.2024. Verfasst von Clémence M Canivet und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, Angers, France. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Liver Diseases, Alcoholic, Metabolic Diseases. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In June 2023, under the patronage of the American Association for Study of Liver Disease, the European Association for Study of the Liver, and the Asociación Latinoamericana para el Estudio del Hígado with the involvement of 236 participants from around the world, a new nomenclature and definition for nonalcoholic fatty liver disease (NAFLD) has been proposed. Metabolic dysfunction-associated steatotic liver disease (MASLD) was defined as presence of hepatic steatosis and at least one of the cardiometabolic risk factors with alcohol intake less than 140 g/wk for women and 210 g/wk for men and no other causes of steatosis. A new entity called combined metabolic dysfunction- and alcohol-associated liver disease (MetALD) was created outside of pure MASLD for patients with metabolic dysfunction and alcohol intake greater than that allowed for MASLD (i.e., 140–350 g/wk for women and 210–420 g/wk for men). Recent studies have confirmed a 95% overlap between NAFLD and the new MASLD diagnostic criteria. Natural history, biomarkers, and thresholds of alcohol intake in MetALD group remains to be studied and validated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseLiver Diseases, AlcoholicMetabolic DiseasesMaleHumansFemaleAlcohol Drinking

Autor:innen und Institutionen

  • Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, Angers, France.
  • HIFIH Laboratory UPRES EA3859, Angers University, Angers, France.
  • Division of Gastroenterology and Hepatology, Department of Medicine, MASLD Research Center, University of California at San Diego, La Jolla, California.

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIAAA NIH HHS

Zitieren

APA

Canivet, C. M., Boursier, J., & Loomba, R. (2024). New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice. Seminars in Liver Disease, 44(01), 035-042. https://doi.org/10.1055/s-0044-1785196

Vancouver

Canivet CM, Boursier J, Loomba R. New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice. Seminars in Liver Disease. 2024;44(01):035-042. doi:10.1055/s-0044-1785196

BibTeX
@article{Canivet2024,
  author = {Canivet, Clémence M and Boursier, Jérôme and Loomba, Rohit},
  title = {New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice},
  journal = {Seminars in Liver Disease},
  year = {2024},
  volume = {44},
  number = {01},
  pages = {035--042},
  doi = {10.1055/s-0044-1785196}
}
Kostenlos starten →